Aptose Biosciences INC. (APTOF) — 8-K Filings

All 8-K filings from Aptose Biosciences INC.. Browse 50 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (50)

Aptose Biosciences Files 8-K: Material Agreement & Officer Comp Changes — Mar 23, 2026
Aptose Biosciences Inc. filed an 8-K on March 23, 2026, reporting an "Entry into a Material Definitive Agreement" and changes in "Compensatory Arrangements of C
Aptose Biosciences Files 8-K — Dec 19, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on December 19, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly kno
Aptose Biosciences Files 8-K with Regulatory Updates — Dec 8, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on December 8, 2025, reporting events as of December 6, 2025. The filing includes a Regulation FD Disclosure and Financial
Aptose Biosciences Inc. Signs Material Definitive Agreement — Nov 25, 2025 Risk: medium
Aptose Biosciences Inc. entered into a material definitive agreement on November 18, 2025. The company, previously known as Lorus Therapeutics Inc. and Imutec P
Aptose Biosciences Files 8-K — Nov 19, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on November 19, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly kno
Aptose Biosciences Files 8-K on Financials — Nov 13, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K report on November 13, 2025, to disclose information regarding its results of operations and financial condition, as well a
Aptose Biosciences Files 8-K — Nov 3, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on November 3, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly know
Aptose Biosciences Files 8-K Report — Oct 16, 2025 Risk: low
On October 16, 2025, Aptose Biosciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits.
Aptose Biosciences Files 8-K — Sep 22, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on September 22, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly
Aptose Biosciences Inc. Announces Board and Officer Changes — Aug 27, 2025 Risk: medium
Aptose Biosciences Inc. announced on August 19, 2025, changes related to its board of directors and officers. The filing details the departure of certain direct
Aptose Biosciences Files 8-K — Aug 25, 2025 Risk: medium
Aptose Biosciences Inc. filed an 8-K on August 25, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial
Aptose Biosciences Files 8-K — Aug 22, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on August 22, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly know
Aptose Biosciences Files 8-K with Regulatory Updates — Aug 18, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on August 18, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
Aptose Biosciences Files 8-K on Financials — Aug 13, 2025 Risk: medium
Aptose Biosciences Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statement
Aptose Biosciences Files 8-K — Aug 6, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on August 6, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
Aptose Biosciences Files 8-K — Jul 15, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on July 15, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly know
Aptose Biosciences Inc. Enters Material Definitive Agreement — Jul 2, 2025 Risk: medium
On June 24, 2025, Aptose Biosciences Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as L
Aptose Biosciences Files 8-K — Jul 1, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on July 1, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as
Aptose Biosciences Enters Material Definitive Agreement — Jun 26, 2025 Risk: medium
Aptose Biosciences Inc. entered into a material definitive agreement on June 20, 2025, which involves a direct financial obligation. The company, formerly known
Aptose Biosciences Files 8-K on June 20, 2025 — Jun 20, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on June 20, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD disclosur
Aptose Biosciences Inc. Announces Board and Compensation Changes — Jun 18, 2025 Risk: medium
Aptose Biosciences Inc. announced on June 16, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure
Aptose Biosciences Inc. Files 8-K Report — Jun 17, 2025 Risk: low
On June 17, 2025, Aptose Biosciences Inc. filed an 8-K report. The filing indicates the company's jurisdiction of incorporation is Canada and provides its busin
Aptose Biosciences Files 8-K — Jun 12, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on June 12, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known a
Aptose Biosciences Files 8-K — May 28, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on May 28, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial sta
Aptose Biosciences Files 8-K — May 20, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on May 20, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as
Aptose Biosciences Files 8-K — May 14, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on May 14, 2025, reporting on financial statements and exhibits, and a Regulation FD Disclosure. The company, formerly know
Aptose Biosciences Files 8-K on Financials — May 8, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on May 8, 2025, reporting on its results of operations and financial condition. The filing also includes financial statemen
Aptose Biosciences Files 8-K — May 5, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on May 5, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as
Aptose Biosciences Files 8-K — Apr 23, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on April 23, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
Aptose Biosciences Changes Auditors — Apr 21, 2025 Risk: low
Aptose Biosciences Inc. announced on April 15, 2025, a change in its certifying accountant. The company has dismissed PricewaterhouseCoopers LLP as its independ
Aptose Biosciences Faces NASDAQ Delisting Notice — Apr 3, 2025 Risk: high
Aptose Biosciences Inc. filed an 8-K on April 3, 2025, reporting a notice of delisting or failure to meet continued listing standards with NASDAQ, effective Mar
Aptose Biosciences Inc. Files 8-K — Apr 1, 2025 Risk: low
On April 1, 2025, Aptose Biosciences Inc. filed an 8-K report. The filing indicates the company's primary business is in Biological Products, specifically exclu
Aptose Biosciences Files 8-K on Financials — Mar 28, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on March 28, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhi
Aptose Biosciences Files 8-K: Material Agreement & Equity Sales — Mar 24, 2025 Risk: medium
On March 18, 2025, Aptose Biosciences Inc. entered into a material definitive agreement and reported unregistered sales of equity securities. The filing also in
Aptose Biosciences Files 8-K — Mar 17, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on March 17, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known
Aptose Biosciences Files 8-K with Exhibits — Mar 12, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on March 11, 2025, reporting financial statements and exhibits. The company, formerly known as Lorus Therapeutics Inc. and
Aptose Biosciences Files 8-K on Security Holder Rights — Feb 21, 2025 Risk: medium
Aptose Biosciences Inc. filed an 8-K on February 21, 2025, reporting events as of February 18, 2025. The filing indicates material modifications to the rights o
Aptose Biosciences Inc. Files 8-K Report — Feb 20, 2025 Risk: low
On February 20, 2025, Aptose Biosciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
Aptose Biosciences Files 8-K — Feb 18, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on February 18, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly kno
Aptose Biosciences Inc. Files 8-K: Material Agreement & Equity Sales — Feb 13, 2025 Risk: medium
Aptose Biosciences Inc. announced on February 7, 2025, that it entered into a material definitive agreement. The company also disclosed unregistered sales of eq
Aptose Biosciences Files 8-K — Feb 13, 2025 Risk: low
On February 13, 2025, Aptose Biosciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits
Aptose Biosciences Inc. Files 8-K — Feb 12, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on February 12, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
Aptose Biosciences Inc. Files 8-K for Material Agreement — Feb 3, 2025 Risk: medium
On February 3, 2025, Aptose Biosciences Inc. filed an 8-K report detailing a material definitive agreement. The company, previously known as Lorus Therapeutics
Aptose Biosciences Inc. Files 8-K on Shareholder Vote Matters — Jan 28, 2025 Risk: medium
Aptose Biosciences Inc. filed an 8-K on January 28, 2025, reporting on matters submitted to a vote of its security holders as of January 27, 2025. The company,
Aptose Biosciences Faces Delisting Concerns — Jan 21, 2025 Risk: high
Aptose Biosciences Inc. filed an 8-K on January 21, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a tran
Aptose Biosciences Files 8-K Report — Jan 13, 2025 Risk: low
On January 13, 2025, Aptose Biosciences Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating updates or disclos
Aptose Biosciences Inc. Files 8-K — Jan 10, 2025 Risk: low
Aptose Biosciences Inc. filed an 8-K on January 10, 2025, reporting events as of January 9, 2025. The filing is a Regulation FD Disclosure and includes Financia
Aptose Biosciences Inc. Files 8-K Report — Dec 19, 2024 Risk: low
On December 19, 2024, Aptose Biosciences Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
Aptose Biosciences Files 8-K — Dec 12, 2024 Risk: low
Aptose Biosciences Inc. filed an 8-K on December 12, 2024, reporting under Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
Aptose Biosciences Files 8-K — Dec 9, 2024 Risk: low
Aptose Biosciences Inc. filed an 8-K on December 9, 2024, reporting on Regulation FD disclosures and financial statements. The company, formerly known as Lorus

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX